Article

A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients.

Service de Pneumologie, University Hospital, Strasbourg, France.
European Respiratory Journal (Impact Factor: 6.36). 11/1999; 14(5):1002-8. DOI: 10.1183/09031936.99.14510029
Source: PubMed

ABSTRACT The beneficial effects of nocturnal oxygen therapy (NOT) in chronic obstructive pulmonary disease (COPD) patients with mild-to-moderate daytime hypoxaemia (arterial oxygen tension (Pa,O2) in the range 7.4-9.2 kPa (56-69 mmHg)) and exhibiting sleep-related oxygen desaturation remains controversial. The effectiveness of NOT in that category of COPD patients was studied. The end points included pulmonary haemodynamic effects after 2 yrs of follow-up, survival and requirement for long-term oxygen therapy (LTOT). Seventy-six patients could be randomized, 41 were allocated to NOT and 35 to no NOT (control). The goal of NOT was to achieve an arterial oxygen saturation of >90% throughout the night. All these patients underwent polysomnography to exclude an associated obstructive sleep apnoea syndrome. The two groups exhibited an identical meansD daytime Pa,O2 of 8.4+/-0.4 kPa (63+/-3 mmHg) at baseline. Twenty-two patients (12 in the NOT group and 10 in the control group, p=0.98) required LTOT during the whole follow-up (35+/-14 months). Sixteen patients died, nine in the NOT group and seven in the control group (p=0.84). Forty-six patients were able to undergo pulmonary haemodynamic re-evaluation after 2 yrs, 24 in the NOT and 22 in the control group. In the control group, mean resting pulmonary artery pressure increased from 19.8+/-5.6 to 20.5+6.5 mmHg, which was not different from the change in mean pulmonary artery pressure in the NOT group, from 18.3+/-4.7 to 19.5+/-5.3 mmHg (p= 0.79). Nocturnal oxygen therapy did not modify the evolution of pulmonary haemodynamics and did not allow delay in the prescription of long-term oxygen therapy. No effect of NOT on survival was observed, but the small number of deaths precluded any firm conclusion. These results suggest that the prescription of nocturnal oxygen therapy in isolation is probably not justified in chronic obstructive pulmonary disease patients.

0 Bookmarks
 · 
113 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: COPD is one of the commonest causes of morbidity and mortality in the world and is increasing in prevalence. Current therapies are not very effective and no current treatment prevents the relentless progression of airflow limitation that characterizes this disease. Smoking cessation is the only strategy that reduces this decline in lung function and, although bupropion is the most effective aid to quitting, more effective treatments of nicotine addition are needed. The mainstay of treatment is bronchodilators for symptom relief and inhaled anticholinergics and beta2-agonists are useful by reducing hyperinflation of the lungs. A new once daily inhaled anticholinergic is the most effective bronchodilator, but long-acting inhaled beta2-agonsts are also useful. Theophylline is used as an additional bronchodilator in more severe patients and may have some anti-inflammatory action. By contrast, inhaled corticosteroids are poorly effective and do not reduce disease profession, although recent studies with combination inhalers (corticosteroid + long-acting beta2-agonist) have shown better effects. Long-term oxygen therapy is needed by patients with pulmonary hypertension and right heart failure. There is a pressing need to develop new classes of therapy, and several new drugs are currently in development, including inteleukin-8 antagonists, phosphodiesterase-4 inhibitors, protease inhibitors and antioxidants.
    Transactions of the Medical Society of London 08/2013; 119:41-51.
  • Source
    Revue des Maladies Respiratoires 03/2014; 31(3):263-94. · 0.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Oxygen therapy is defined as the therapeutic use of oxygen and consists of administering oxygen at higher concentrations than those found in room air, with the aim of treating or preventing hypoxia. This therapeutic intervention has been shown to increase survival in patients with chronic obstructive pulmonary disease (COPD) and respiratory failure. Although this concept has been extended by analogy to chronic respiratory failure caused by respiratory and non-respiratory diseases, continuous oxygen therapy has not been shown to be effective in other disorders. Oxygen therapy has not been shown to improve survival in patients with COPD and moderate hypoxaemia, nor is there consensus regarding its use during nocturnal desaturations in COPD or desaturations caused by effort. The choice of the oxygen source must be made on the basis of criteria such as technical issues, patient comfort and adaptability and cost. Flow must be adjusted to achieve appropriate transcutaneous oxyhaemoglobin saturation correction.
    Archivos de Bronconeumología 01/2014; · 2.17 Impact Factor

Full-text (2 Sources)

View
22 Downloads
Available from
May 23, 2014